Emory University psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Emory University is listed with 6 registered studies counted here, in Atlanta, United States. By compound: 2 psilocybin, 2 MDMA and 2 ketamine. By registry status: 3 recruiting, 1 not yet recruiting, 1 enrolling by invitation and 1 completed. By phase: 1 early phase 1, 1 phase 1 and 4 phase 2. Reported start years run from 2022 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 6 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 2 |
| MDMA | 2 |
| Ketamine | 2 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 3 | 50% |
| Not yet recruiting | 1 | 17% |
| Enrolling by invitation | 1 | 17% |
| Completed | 1 | 17% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 17% |
| Phase 1 | 1 | 17% |
| Phase 2 | 4 | 67% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Electrophysiologic Mechanisms of Ketamine Antidepressant Response | NCT07768618 | Not yet recruiting | Phase 2 | 2026-12-01 | Ketamine |
| Psilocybin-Assisted Randomized Therapy | NCT07332143 | Recruiting | Phase 2 | 2026-03-01 | Psilocybin |
| MDMA-Assisted Massed Exposure Therapy for PTSD | NCT07288151 | Recruiting | Phase 2 | 2026-01-01 | MDMA |
| MDMA Plus Exposure Therapy for PTSD | NCT05746572 | Enrolling by invitation | Phase 2 | 2024-02-13 | MDMA |
| Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine | NCT05327699 | Recruiting | Early Phase 1 | 2022-11-08 | Ketamine |
| Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain | NCT05506982 | Completed | Phase 1 | 2022-11-01 | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | Ketamine